VITA 34 AG Market Cap ($56.66 Million)
Market Cap & Net Worth: VITA 34 AG (V3V)
VITA 34 AG market cap. VITA 34 AG (XETRA:V3V) has a market capitalization of $56.66 Million (€48.46 Million) as of November 1, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #21225 globally and #1907 in its home market, demonstrating a -0.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VITA 34 AG's stock price €2.78 by its total outstanding shares 17431762 (17.43 Million). Also see cash flow conversion of VITA 34 AG for how efficiently the company converts equity into cash flow.
VITA 34 AG Market Cap History (2015–2026)
VITA 34 AG market cap history from 2015 to 2026. Data shows change from $90.10 Million to $56.66 Million (-4.55% CAGR). Check V3V stock price for real-time trading data and today's change.
VITA 34 AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VITA 34 AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VITA 34 AG equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.39x
VITA 34 AG's market cap is 1.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $105.85 Million | $16.29 Million | $408.00K | 6.50x | 259.44x |
| 2017 | $224.40 Million | $19.19 Million | -$322.00K | 11.70x | N/A |
| 2018 | $219.62 Million | $20.41 Million | $828.00K | 10.76x | 265.25x |
| 2019 | $259.84 Million | $20.25 Million | $1.35 Million | 12.83x | 192.47x |
| 2020 | $255.76 Million | $20.07 Million | $1.45 Million | 12.74x | 176.51x |
| 2021 | $305.69 Million | $28.42 Million | -$3.93 Million | 10.76x | N/A |
| 2022 | $159.37 Million | $68.94 Million | -$27.39 Million | 2.31x | N/A |
| 2023 | $106.79 Million | $77.06 Million | -$1.86 Million | 1.39x | N/A |
| 2024 | $83.96 Million | $82.18 Million | -$12.14 Million | 1.02x | N/A |
| 2025 | $122.28 Million | $88.17 Million | -$6.30 Million | 1.39x | N/A |
Competitor Companies of V3V by Market Capitalization
Companies near VITA 34 AG in the global market cap rankings as of November 1, 2026. Also see V3V asset base for a full breakdown of the balance sheet.
Key companies related to VITA 34 AG by market ranking:
- HCA Healthcare, Inc. (NYSE:HCA): Ranked #284 globally with a market cap of $91.34 Billion USD.
- Fresenius SE & Co. KGaA (XETRA:FRE): Ranked #901 globally with a market cap of $29.19 Billion USD ( €24.97 Billion EUR).
- FRESENIUS SE+CO. ADR 1/4 (F:FREA): Ranked #987 globally with a market cap of $26.87 Billion USD ( €22.98 Billion EUR).
- Tenet Healthcare Corporation (NYSE:THC): Ranked #1210 globally with a market cap of $20.93 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #284 | HCA Healthcare, Inc. | NYSE:HCA | $91.34 Billion | $473.19 |
| #901 | Fresenius SE & Co. KGaA | XETRA:FRE | $29.19 Billion | €47.80 |
| #987 | FRESENIUS SE+CO. ADR 1/4 | F:FREA | $26.87 Billion | €10.20 |
| #1210 | Tenet Healthcare Corporation | NYSE:THC | $20.93 Billion | $273.25 |
Market Capitalization of VITA 34 AG (2015–2026)
Market capitalization of VITA 34 AG from 2015 to today. Between 2015 and today, VITA 34 AG's market cap moved from $90.10 Million to $ 56.66 Million, with a yearly change of -4.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €56.66 Million | -53.67% |
| 2025 | €122.28 Million | +45.63% |
| 2024 | €83.96 Million | -21.37% |
| 2023 | €106.79 Million | -32.99% |
| 2022 | €159.37 Million | -47.87% |
| 2021 | €305.69 Million | +19.52% |
| 2020 | €255.76 Million | -1.57% |
| 2019 | €259.84 Million | +18.31% |
| 2018 | €219.62 Million | -2.13% |
| 2017 | €224.40 Million | +111.99% |
| 2016 | €105.85 Million | +17.49% |
| 2015 | €90.10 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of VITA 34 AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $56.66 Million USD |
| MoneyControl | $56.66 Million USD |
| MarketWatch | $56.66 Million USD |
| marketcap.company | $56.66 Million USD |
| Reuters | $56.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VITA 34 AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more